Plaque Psoriasis drug, Ixekizumab, reported improved work productivity, high levels of skin clearance in Phase 3 trials
by Staff from Outbreak News Today on (#16EWT)
Eli Lilly and Company announced Monday that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work productivity in patients with moderate-to-severe plaque psoriasis. Specific results from the UNCOVER-1 study were also presented Monday during the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C. In ["]
